May 13, 2019

Glasgow healthcare data start-up, Talking Medicines, founded by Jo Halliday, Scott Crae and Elizabeth Fairley, has secured its first institutional investment as part of a new funding round worth £622,000 to support the next stage of its growth.

Founded in 2013, Talking Medicines has developed and launched the Medsmart®  App which can help patients better manage their medicines at home. Aimed at ensuring medicines are taken at the right time, in the right way and for the correct duration, Medsmart® transforms complex information for medicines into easy to understand content for the user.

Talking Medicine’s latest funding round was led by SIS Ventures, and included investment from private investors and founders of the business as well as the Scottish Investment Bank, the investment arm of Scottish Enterprise. It is the third seed investment round to have been successfully completed by the business. This takes the amount raised by the company to £1.2M for Medsmart® over the past two years.

This round of investment will support the company’s growth plans across the technical development of both the Medsmart® tools and the data mining capabilities to accelerate growth in the UK and globally. Medsmart® disrupts the way in which Pharmaceutical companies access real world data, allowing them to see how their medicines are used in the real world.

Jo Halliday, founder and chief executive of Talking Medicines commented: “This latest investment round demonstrates the growing support around the vision of enriching the experience of patients and understanding how their medicines are being taken. The Medsmart® App is in the 30,000-50,000 download bracket and the data insights are being accessed by marketing teams from a number of pharmaceutical clients. We have a vision to open up the traditional data model for the pharmaceutical industry and today marks an important milestone in that journey.”

For SIS Ventures, the mission-led investment arm of responsible finance provider Social Investment Scotland (SIS), investment in Talking Medicines marks the first equity investment to be made by the firm’s Impact First fund, a private investor fund launched in 2018 to support Scotland’s high impact enterprises.

Benefiting from both Enterprise Investment Scheme (EIS) relief and Social Investment Tax Relief (SITR), Impact First will eventually offer investors a portfolio of between six and twelve high-growth potential, high-impact enterprises which aim to tackle a clearly identifiable social problem with a scalable and disruptive business solution.

Thomas Gillan, director, SIS Ventures, said: “We’re delighted to have made our first investment in such a purpose-led, impact-focused business as Talking Medicines. Although still a young company, Talking Medicines has established strong initial traction with consumers, pharmaceutical companies and the investor community. Working with Jo and the team, we’re looking forward to supporting them on their journey to becoming the global gold standard for real world insights on consumer usage of medicines.”

Kerry Sharp, Director of SIB, commented: “This deal represents an exciting progression in the growth of Talking Medicines. Scottish Enterprise has supported the company throughout its evolution through account management, SMART: SCOTLAND innovation support and Jo’s participation in the Unlocking Ambition challenge. We are delighted to support Talking Medicines’ long term ambitions to establish a high growth business with a clear social conscience that will benefit our communities.”

Recent Blogs

Week 9 of government advised lockdown: COVID-19 survey update

Week 9 of government advised lockdown: COVID-19 survey update

Talking Medicines have now captured 1,827 responses across five surveys showing the public opinions to COVID-19. Outreach engagement is via direct Facebook from the Medsmart® community to understand the attitudes, views and behaviour changes in the community towards...

COVID-19 – Why the gender disparity?

COVID-19 – Why the gender disparity?

Over the last few weeks there has been a lot of speculation over what exacerbates an individual’s response to coronavirus and why there is such great disparity in the gender of those dying from this virus. One explanation being explored is the effect of Angiotensin...

Old drug, new tricks?

Old drug, new tricks?

As a population, two viable options are presented for us to escape our virus-inflicted confinement: gain herd immunity or find a vaccine. The former is a perilous tactic, that carries the risk of many more fatalities and no guarantee of immunity post-infection. The...